Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study ID
NCT04569916
Phase
PHASE2
Status
Unknown

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • radiotherapy — RADIATION
    radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
  • irinotecan liposome — DRUG
    radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
  • apatinib — DRUG
    radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
  • PD-1 antibody — DRUG
    radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Study Details

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

Key Dates

Start date
Sep 30, 2020
Status verified
Sep 2020
Primary completion
Feb 28, 2023
Completion
May 31, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Primary Outcome Measure

Objective Response Rate [ Time Frame: 2 years ]

Central Contacts

Related Studies